AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...
China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...
China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...
On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...
China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...
China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197)...